STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients. 

Its next act — this time as a co-lead — was revealed Monday.

Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat along with Revolution’s daraxonrasib led to a durable responses in the large majority of pancreatic cancer patients who received both medicines. 

Continue to STAT+ to read the full story…